Oncogenic PIK3CA corrupts growth factor signaling specificity by Ralitsa R Madsen, Alix Le Marois, Oliwia N Mruk, Margaritis Voliotis, Shaozhen Yin, Jahangir Sufi, Xiao Qin, Salome J Zhao, Julia Gorczynska, Daniele Morelli, Lindsay Davidson, Erik Sahai, Viktor I Korolchuk, Christopher J Tape, Bart Vanhaesebroeck

“…Using this framework, we found that the PIK3CA H1047R oncogene was not a simple, constitutive activator of the pathway as often presented. …”
Get full text

Comprehensive landscape and oncogenic role of extrachromosomal circular DNA in malignant biliary strictures by Zhuo Cheng, Xuanmei Luo, Wenzheng Liu, Xiaofang Lu, Hong Chang, Yingchun Wang, Wei Zheng, Xiue Yan, Yonghui Huang

Get full text

Key oncogenes and candidate drugs for hepatitis-B-driven hepatocellular carcinoma progression by Liqin Ruan, Ningbo Fang, Xinhua Zhao, Weili Chen, Zhaoping Wu, Xiaoyong Wu

Get full text

Overexpression of metalloproteinase PAPPA accelerates cancer progression and correlates with immune cell infiltration in gastric cancer: insights from bioinformatics and in vitro i... by Shiya Yu, Shiyao Zheng, Jinwei Qiu, Hongming Lin, Xiaojuan Yu, Huiyan Chen, Junhong Wu, Weihang Wu, Jiong Chen, Yongyuan Chen, Jianwei Chen, Hu Zhao, Yu Wang

Subjects: Get full text

PTOV1 exerts pro-oncogenic role in colorectal cancer by modulating SQSTM1-mediated autophagic degradation of p53 by Yongli Fan, Yuqin Li, Xia Luo, Shiqi Xiang, Jia Hu, Jingchun Zhan, Weilong Chang, Rui Deng, Xianwen Ran, Yize Zhang, Yudie Cai, Weiwei Zhu, Huifen Wang, Zhibo Liu, Di Wang

“…Conclusion Our study unveils the oncogenic role of PTOV1 in CRC progression, which was achieved by promoting SQSTM1 directed autophagic degradation of p53. …”
Get full text

Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome– paving the path towards precision medicine: a case report by Carolin Seeling, Sonja Dahlum, Ralf Marienfeld, Vera Jan, Brigitte Rack, Uwe Gerstenmaier, Ambros J. Beer, Regine Mayer-Steinacker, Wolfgang Thaiss, Thomas F. E. Barth, Thomas Seufferlein, Nadine T. Gaisa, Stephan Stilgenbauer, Wolfgang Janni, Reiner Siebert, Hartmut Döhner, Verena I. Gaidzik

“…Conclusions In the era of accessible and comprehensive genetic and phenotypic tumor profiling, this case study of a patient with Li-Fraumeni syndrome underscores the success of precision oncology in harnessing additional somatic oncogenic driver alterations. Furthermore, it emphasizes the indispensable role of an interdisciplinary molecular tumor board, enhancing the awareness of molecular profiling and targeted therapies in patients with rare cancer susceptibility disorders.…”
Get full text

Inhibition of Ultraviolet B-induced Apoptosis in Fibroblasts by Human Umbilical Cord Blood Mesenchymal Stem Cell Conditioned Media via the Phosphatidylinositol-3-Kinase/Akt Pathway by Ferry Sandra, Dian Andriani Ratna Dewi, I Nyoman Mantik Astawa, Wimpie Pangkahila, Angliana Chouw, Maria Celinna, Nurrani Mustika Dewi

Subjects: Get full text

Production of novel theranostic nano-vector based on superparamagnetic iron oxide nanoparticles/miR-497 targeting colorectal cancer by Asmaa M. Elfiky, May M. Eid, May El-Manawaty, Zeinab A. Elshahid, Elham Mohamed Youssef, Khaled Mahmoud

Subjects: Get full text

Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis by Mariana M. Sebastião, Rodrigo S. Ho, João Paulo V. de Carvalho, Micha Nussbaum

“…The aim of the study was to carry out a systematic review and a meta-analysis in order to determine the accuracy of NGS of ctDNA to detect six oncogenic driver alterations: epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK); ROS proto-oncogene 1, receptor tyrosine kinase (ROS-1); serine/threonine-protein kinase B-RAF (BRAF); RET proto-oncogene (RET); and MET proto-oncogene, receptor tyrosine kinase (MET) exon 14 in patients with aNSCLC. …”
Get full text

Melanoma genomics – will we go beyond BRAF in clinics? by Justyna Mirek, Wiesław Bal, Magdalena Olbryt

“…However, evaluating the oncogene BRAF mutation in codon V600 is still the only companion diagnostic genomic test commonly implemented in clinics for molecularly targeted treatment of advanced melanoma. …”
Get full text

Inhibition of lanosterol synthase linking with MAPK/JNK signaling pathway suppresses endometrial cancer by Liangjian Ma, Wunan Huang, Xiaolei Liang, Hongli Li, Wei Yu, Lexin Liu, Yuelin Guan, Chang Liu, Xiangjun Chen, Lidan Hu

“…These findings establish LSS as a novel oncogene in EC, promoting tumor progression through MAPK/JNK signaling activation and cholesterol ester accumulation, and highlight the therapeutic potential of targeting LSS in EC treatment.…”
Get full text

A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022 by TAN Meijuan, YANG Shijie, XU Xiequn

“…The key areas of focus in highly cited literature were RET proto oncogene, targeted therapy, RET gene mutation, and so on.ConclusionsIn the past 20 years, MTC related research has shown a gradual upward trend, with developed countries led by the United States taking a leading position in this field. …”
Get full text

Nrf2/cyclooxygenase 2 signaling in Cr(VI)-induced carcinogenesis by Lei Zhao, Yi-Fang Wang, Andrea Adamcakova-Dodd, Peter S. Thorne, Ranakul Islam, Ke Jian Liu, Fei Chen, Jia Luo, Ling-Zhi Liu

“…In summary, our study revealed the oncogenic role of COX-2 and identified two novel regulatory mechanisms for COX-2 overexpression in Cr(VI)-induced carcinogenesis.…”
Get full text

Single-nucleotide polymorphisms in dizygotic twin ovine fetuses are associated with discordant responses to antenatal steroid therapy by Erin L. Fee, Haruo Usuda, Sean W. D. Carter, Hideyuki Ikeda, Tsukasa Takahashi, Yuki Takahashi, Yusaku Kumagai, Michael W. Clarke, Demelza J. Ireland, John P. Newnham, Masatoshi Saito, Sebastian E. Illanes, Binny Priya Sesurajan, Liang Shen, Mahesh A. Choolani, Gokce Oguz, Adaikalavan Ramasamy, Sara Ritchie, Andrew Ritchie, Alan H. Jobe, Matthew W. Kemp

“…Genomic analysis identified 13 single-nucleotide polymorphisms (SNPs) statistically associated with ANS-responsiveness, including in the proto-oncogene MET and the transcription activator STAT1. …”
Get full text

Development of animal models to study aggressive thyroid cancers by Shovan Dutta, Jeffrey A Knauf

“…Indeed, mice with a combination of oncogenic drivers and common cooperating alterations have been developed, demonstrating that these alterations function in conjunction with the oncogenic driver to promote the progression to advanced thyroid cancer. …”
Get full text

Beyond immortality: Epstein–Barr virus and the intricate dance of programmed cell death in cancer development by Arezoo Esmaeili, Prankur Awasthi, Samira Tabaee

“…Furthermore, the insights gleaned from this review could catalyze the design of vaccines aimed at preventing EBV infection or curtailing its oncogenic impact. Innovatively, the review synthesizes recent discoveries on the multifaceted roles of non-coding RNAs and cellular signaling pathways in modulating cell death within the context of EBV infection. …”
Get full text

p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. by Karen S Kelly-Spratt, Kay E Gurley, Yutaka Yasui, Christopher J Kemp

“…Ectopic expression of oncogenes such as Ras induces expression of p19(Arf), which, in turn, activates p53 and growth arrest. …”
Get full text

E6AP is essential for the proliferation of HPV-positive cancer cells by preventing senescence. by Alicia Avenhaus, Milica Velimirović, Julia Bulkescher, Martin Scheffner, Felix Hoppe-Seyler, Karin Hoppe-Seyler

“…Oncogenic types of human papillomaviruses (HPVs) are major human carcinogens. …”
Get full text

Inhibition of TFF3 synergizes with c-MET inhibitors to decrease the CSC-like phenotype and metastatic burden in ER+HER2+ mammary carcinoma by Chuyu He, Xuejuan Wang, Yi-Shiou Chiou, Basappa Basappa, Tao Zhu, Vijay Pandey, Peter E. Lobie

“…Targeting TFF3 with an interfering RNA plasmid or a small-molecule inhibitor (AMPC) inhibited these oncogenic characteristics, highlighting the therapeutic potential of targeting TFF3 in ER+HER2+ MC. …”
Get full text

Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer by Jun Sakakibara-Konishi, Hirofumi Takahashi, Kenichiro Ito, Tomoo Ikari, Yasuyuki Ikezawa, Hidenori Kitai, Megumi Furuta, Yuta Takashima, Tetsuaki Shoji, Masahide Fukudo, Satoshi Konno

“…Chromosomal rearrangements of the RET (rearranged during transfection) gene are detected in approximately 1–2% of non-small cell lung cancers (NSCLC) and have function as oncogenic driver genes. Selpercatinib is a highly effective RET inhibitor for RET-rearranged patients with NSCLC and shows mostly tolerable adverse events. …”
Get full text